Epilepsy: Correcting the serotonergic pathogenesis

If the undergoing research ensures fruitful results, then this psychedelic company can create a new future in modern medicine. To be specific, it can create a new pathway of agonism or a treatment regimen, never heard of before with their psychedelic company stocks. Another advantage is that these substances are receptor-specific and, therefore, do not bind to 5-HT2B receptors.